Phase I/II Study of Stereotactic Radiation Therapy and Concurrent and Adjuvant Sutent (SU11248) as Treatment for Oligometastatic Disease
Phase 1/Phase 2
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
Cancer
Both
Cancer
Trial Information
Phase I/II Study of Stereotactic Radiation Therapy and Concurrent and Adjuvant Sutent (SU11248) as Treatment for Oligometastatic Disease
Inclusion Criteria:
- Age 18 years or older
- Histologically or cytologically confirmed diagnosis of metastatic cancer
- No prior RT to currently involved sites
- Informed consent
- ECOG performance status < 2
- Intact organ and bone marrow function
- Obtained informed consent
Exclusion Criteria:
- Under 18 years of age
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
survival
Principal Investigator
Johnny Kao, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Mount Sinai School of Medicine
Authority:
United States: Institutional Review Board
Study ID:
GCO 06-0906
NCT ID:
NCT00463060
Start Date:
January 2007
Completion Date:
Related Keywords:
- Cancer
Name | Location |
|---|---|
| Mount Sinai School of Medicine | New York, New York 10029 |
